Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run
Viatris stock has returned 76.1% over the past year, yet its valuation checks still lean cheap, which puts the recent share price strength under scrutiny for investors trying to judge whether the current level around US$16.43 offers enough long term value support.
- Viatris has delivered a 76.1% gain over the last 12 months, which makes it important to ask whether the current price already reflects much of the good news.
- The recent FDA approval for the once weekly Gwyn Lo contraceptive patch can support expectations for future revenue, while the planned sale of TYRVAYA nasal spray rights to Harrow introduces uncertainty around how Viatris allocates and replaces that product contribution over time.
- On Simply Wall St's broader valuation checks, Viatris screens as undervalued in 5 of 6 areas. As a result, the overall picture leans toward the stock still looking cheap on fundamental metrics.
The issue now is whether Viatris shares still offer a margin of safety after such a strong 1 year run, or if the easy valuation upside has already played out.
Is Viatris a Bargain on Sales?
For Viatris, the P/S ratio is useful because revenue is a more stable anchor than earnings when profits can be volatile.
Viatris trades on a P/S of about 1.3x, compared with a Pharmaceuticals industry average of about 5.0x and a peer group average near 4.7x. The Fair P/S Ratio model, which looks at factors such as the company’s margins, size and risk profile, indicates a level of about 3.5x. That is a wide gap between where the stock trades and where this framework suggests a more typical P/S might sit.
Despite the recent FDA approval for the once weekly Gwyn Lo contraceptive patch, Viatris still trades at a clear discount to the sales multiples seen across its peer group. The current P/S level implies the market is putting a low value on each dollar of revenue compared with similar pharmaceutical companies.
On the P/S multiple, Viatris stock currently appears undervalued relative to both its Fair Ratio and the wider Pharmaceuticals industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Viatris Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Viatris valuation puzzle leaves off. They spell out which assumptions about Viatris' future revenue, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price, and each one treats fair value as a thesis about how the business might develop over time, so you can see how that view holds up as new information emerges on the Community page.
Community views on Viatris sit far apart, with some investors seeing deep value and others arguing expectations already look stretched.
Bull case: 58% undervalued
"Viatris continued to generate massive cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments..."
Read the full Bull Case to see why Viatris could be undervalued
Bear case: 37% overvalued
"Sustained pricing and regulatory pressures are likely to compress margins and increase operating costs across Viatris' core generics business..."
Read the full Bear Case to see why Viatris could be overvalued
Do you think there's more to the story for Viatris? Head over to our Community to see what others are saying!
The Bottom Line
Viatris still screens as undervalued on market multiples, even after a strong 1 year return. The key question is whether the discount is compensation for pressure on the core generics franchise or an opportunity if margins and cash generation hold up. For you as an investor, the crux is whether Viatris can sustain its earnings power and convert new products into durable revenue without eroding profitability. How that plays out will likely decide whether today’s valuation gap closes or proves to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com